C. difficile Vaccine Candidate MVX02

Clostridioides difficile is the most common cause of healthcare associated infections (HAI).  C. difficile infections (CDI) result in 14,000 deaths per year in the United States mainly in older adults who take antibiotics and have prolonged hospital stays.  There is no vaccine for CDI and most vaccine efforts have focused on Toxin A (TcdA) and Toxin B (TcdB), which are primarily responsible for disease symptoms. Toxoid vaccine candidates may provide only limited protection against CDI since they target the toxin(s), but not the bacteria itself.  Thus, a multivalent vaccine that targets both the toxins and the bacterial surface may be a more effective approach to combating CDI.  

Matrivax has a unique, proprietary prophylactic/therapeutic vaccine approach targeting C. difficile infection and relapse, or ‘secondary prophylaxis’. MVX02 is a combination vaccine targeting the toxins and PSII, a conserved cell surface polysaccharide of C. difficile. MXV02 is in preclinical development, with an IND planned in 4Q2021

MVX02: A vaccine intervention targeting the toxin producing bacteria and the toxins

© 2020 Matrivax Research and Development Corporation

650 Albany Street, Suite 117, Boston, MA 02118

LI-In-Bug.png